<DOC>
	<DOCNO>NCT01690598</DOCNO>
	<brief_summary>The purpose study investigate effect combine topotecan veliparib ( ABT888 ) treatment relapsed ovarian cancer tumor progression negative unknown BRCA mutation status .</brief_summary>
	<brief_title>Veliparib Topotecan Relapsed Ovarian Cancer With Negative Unknown BRCA Status</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>1 . Histologically confirm epithelial , primary fallopian primary peritoneal cancer . 2 . Verified progression either RECIST criterion and/or GCIG CA125 criterion previous first line chemotherapy progression later line cytotoxic treatment . 3 . Platinum resistance partially platinum sensitive disease Relapsed within six month prior first line/later line platinumbased therapy Relapsed within sixtwelve month prior first line/later line platinumbased therapy 4 . Age ≥ 18 year . 5 . Performance status 02 . 6 . Measurable disease RECIST 1.1 CA125 GCIG criteria 7 . Adequate bone marrow function , liver function , renal function coagulation parameter ( within 7 day prior enrollment ) : WBC ≥ 3.0 x 10^9/l neutrophil ( ANC ) ≥ 1.5 x 10^9/l Platelet count ≥ 100 x 109/l Hemoglobin ≥ 9.7 g/dl ( 6 mmol/L ) Serum bilirubin ≤ 1.5 x ULN Serum transaminases ≤ 2.5 x ULN Serum creatinine ≤ 1.5 x ULN 8 . Written informed consent . 9 . Tissue available BRCAness analysis/BRCA mutation analysis . 1 . Prior treatment PARP inhibitor . 2 . Patients BRCA1/2 germline mutation . 3 . Platinumrefractory disease ( disease progress stable prior platinum therapy ) 4 . Patients receive ( plan receive ) treatment investigational agent , participate another clinical trial within 28 day prior enter trial . 5 . Pregnant breastfeeding . For fertile woman negative pregnancy test screen mandatory . 6 . Fertile patient willing use acceptable safe method contraception 6 month treatment 7 . Other present previous malignancy except curatively treated cervical cancer stage I , nonmelanotic skin cancer cancer minimal risk relapse . Previous breast cancer allow , disease free followup least five year prior enrollment . 8 . CNS metastasis . 9 . History chronic medical psychiatric condition laboratory abnormality , medically control opinion Investigator may increase risk associated study drug administration ( e.g . diabetes , cardiac disease , hypertension , renal liver disease ) . 10 . Allergy ingredient study medication .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Epithelial ovarian cancer</keyword>
	<keyword>BRCA mutation</keyword>
	<keyword>Platinum resistant</keyword>
	<keyword>Platinum sensitive</keyword>
	<keyword>Relapsed ovarian cancer</keyword>
</DOC>